Breaking News Instant updates and real-time market news.

WILLF

Demant

$0.00 /

+ (+0.00%)

04:55
02/19/20
02/19
04:55
02/19/20
04:55

Demant management to meet with JPMorgan

Meeting to be held in Toronto on February 19 hosted by JPMorgan.

  • 19

    Feb

WILLF Demant
$0.00 /

+ (+0.00%)

01/16/20 Jefferies
Jefferies European team revamps Franchise Picks list with nine additions
10/31/19 Goldman Sachs
Demant downgraded to Sell from Neutral at Goldman Sachs
09/10/19 Jefferies
Demant upgraded to Buy from Hold at Jefferies

TODAY'S FREE FLY STORIES

Recommendations
Iovance Biotherapeutics price target raised to $53 from $44 at Chardan » 08:00
08/07/20
08/07
08:00
08/07/20
08:00
IOVA

Iovance Biotherapeutics

$31.21 /

+0.33 (+1.07%)

Chardan analyst Geulah…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

05/29/20 Piper Sandler
Piper says Iovance data for lifileucel continue to 'mature favorably'
05/28/20 Piper Sandler
Iovance melanoma data 'fully supportive of approval,' says Piper Sandler
04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

  • 29
    May
IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

IOVA Iovance Biotherapeutics
$31.21 /

+0.33 (+1.07%)

Recommendations
Yelp price target raised to $29 from $21 at RBC Capital » 07:54
08/07/20
08/07
07:54
08/07/20
07:54
YELP

Yelp

$26.70 /

+0.07 (+0.26%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YELP Yelp
$26.70 /

+0.07 (+0.26%)

YELP Yelp
$26.70 /

+0.07 (+0.26%)

08/06/20 Baird
Yelp price target raised to $26 from $22 at Baird
06/10/20 BTIG
Yelp initiated with a Neutral at BTIG
06/10/20 Citi
Yelp price target raised to $26 from $21 at Citi
05/11/20
Fly Intel: Top five analyst downgrades
YELP Yelp
$26.70 /

+0.07 (+0.26%)

YELP Yelp
$26.70 /

+0.07 (+0.26%)

YELP Yelp
$26.70 /

+0.07 (+0.26%)

YELP Yelp
$26.70 /

+0.07 (+0.26%)

Earnings
Orgenesis reports Q2 revenue $1.7M vs. $1.1M last year » 07:54
08/07/20
08/07
07:54
08/07/20
07:54
ORGS

Orgenesis

$5.38 /

-0.08 (-1.47%)

Vered Caplan, CEO of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ORGS Orgenesis
$5.38 /

-0.08 (-1.47%)

ORGS Orgenesis
$5.38 /

-0.08 (-1.47%)

09/26/19 Benchmark
Orgenesis initiated with a Speculative Buy at Benchmark
ORGS Orgenesis
$5.38 /

-0.08 (-1.47%)

Downgrade
Jefferies downgrades 'show-me story' TherapeuticsMD to Underperform » 07:53
08/07/20
08/07
07:53
08/07/20
07:53
TXMD

TherapeuticsMD

$1.62 /

-0.42 (-20.59%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TXMD TherapeuticsMD
$1.62 /

-0.42 (-20.59%)

TXMD TherapeuticsMD
$1.62 /

-0.42 (-20.59%)

04:47 Today Jefferies
TherapeuticsMD downgraded to Underperform from Hold at Jefferies
05/19/20
Fly Intel: Top five analyst downgrades
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral on COVID disruptions at JPMorgan
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral from Overweight at JPMorgan
TXMD TherapeuticsMD
$1.62 /

-0.42 (-20.59%)

  • 25
    Oct
TXMD TherapeuticsMD
$1.62 /

-0.42 (-20.59%)

TXMD TherapeuticsMD
$1.62 /

-0.42 (-20.59%)

Earnings
Flowers Foods targets long-term EPS growth of 7%-9% » 07:52
08/07/20
08/07
07:52
08/07/20
07:52
FLO

Flowers Foods

$23.40 /

+0.16 (+0.69%)

Flowers Foods updated its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FLO Flowers Foods
$23.40 /

+0.16 (+0.69%)

FLO Flowers Foods
$23.40 /

+0.16 (+0.69%)

05/15/20 SunTrust
Flowers Foods price target raised to $25 from $20 at SunTrust
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
FLO Flowers Foods
$23.40 /

+0.16 (+0.69%)

FLO Flowers Foods
$23.40 /

+0.16 (+0.69%)

Upgrade
iRhythm upgraded to Buy from Neutral at Colliers » 07:51
08/07/20
08/07
07:51
08/07/20
07:51
IRTC

iRhythm

$183.99 /

-5.84 (-3.08%)

Colliers analyst Eugene…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IRTC iRhythm
$183.99 /

-5.84 (-3.08%)

IRTC iRhythm
$183.99 /

-5.84 (-3.08%)

06:47 Today Citi
iRhythm price target raised to $215 from $200 at Citi
08/05/20 Canaccord
iRhythm price target raised to $189 from $130 at Canaccord
08/05/20 Oppenheimer
iRhythm upgraded to Outperform at Oppenheimer
08/05/20 Oppenheimer
iRhythm upgraded to Outperform from Perform at Oppenheimer
IRTC iRhythm
$183.99 /

-5.84 (-3.08%)

  • 06
    Sep
IRTC iRhythm
$183.99 /

-5.84 (-3.08%)

Earnings
Ebix not providing 2020 guidance » 07:51
08/07/20
08/07
07:51
08/07/20
07:51
EBIX

Ebix

$24.01 /

+0.5 (+2.13%)

Given the ongoing market…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EBIX Ebix
$24.01 /

+0.5 (+2.13%)

EBIX Ebix
$24.01 /

+0.5 (+2.13%)

05/12/20 Craig-Hallum
Ebix shares and estimates 'have put in a floor,' says Craig-Hallum
05/12/20 BMO Capital
Ebix price target lowered to $34 from $43 at BMO Capital
04/30/20 Craig-Hallum
Ebix price target lowered to $75 from $80 at Craig-Hallum
03/26/20 Craig-Hallum
Ebix to be top performer as investors realize stock mispriced, says Craig-Hallum
EBIX Ebix
$24.01 /

+0.5 (+2.13%)

EBIX Ebix
$24.01 /

+0.5 (+2.13%)

Earnings
Ebix reports Q2 adj. EPS 88c, two est. 38c » 07:50
08/07/20
08/07
07:50
08/07/20
07:50
EBIX

Ebix

$24.01 /

+0.5 (+2.13%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EBIX Ebix
$24.01 /

+0.5 (+2.13%)

EBIX Ebix
$24.01 /

+0.5 (+2.13%)

05/12/20 Craig-Hallum
Ebix shares and estimates 'have put in a floor,' says Craig-Hallum
05/12/20 BMO Capital
Ebix price target lowered to $34 from $43 at BMO Capital
04/30/20 Craig-Hallum
Ebix price target lowered to $75 from $80 at Craig-Hallum
03/26/20 Craig-Hallum
Ebix to be top performer as investors realize stock mispriced, says Craig-Hallum
EBIX Ebix
$24.01 /

+0.5 (+2.13%)

EBIX Ebix
$24.01 /

+0.5 (+2.13%)

Recommendations
Wix.com price target raised to $350 from $305 at Oppenheimer » 07:50
08/07/20
08/07
07:50
08/07/20
07:50
WIX

Wix.com

$307.71 /

-1.51 (-0.49%)

Oppenheimer analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WIX Wix.com
$307.71 /

-1.51 (-0.49%)

WIX Wix.com
$307.71 /

-1.51 (-0.49%)

06:38 Today JMP Securities
Wix.com price target raised to $363 from $210 at JMP Securities
07/23/20 Citi
Wix.com price target raised to $330 from $220 at Citi
07/22/20 KeyBanc
Wix.com price target raised to $325 from $275 at KeyBanc
07/16/20 Oppenheimer
Wix.com price target raised to $305 from $205 at Oppenheimer
WIX Wix.com
$307.71 /

-1.51 (-0.49%)

WIX Wix.com
$307.71 /

-1.51 (-0.49%)

WIX Wix.com
$307.71 /

-1.51 (-0.49%)

Downgrade
Prestige Consumer downgraded to Neutral from Buy at DA Davidson » 07:50
08/07/20
08/07
07:50
08/07/20
07:50
PBH

Prestige Consumer

/

+

DA Davidson analyst Linda…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PBH Prestige Consumer
/

+

PBH Prestige Consumer
/

+

06:59 Today DA Davidson
Prestige Consumer downgraded to Neutral from Buy at DA Davidson
06/29/20 Sidoti
Prestige Consumer upgraded to Buy from Neutral at Sidoti
04/15/20 DA Davidson
Prestige Consumer price target raised to $47 from $43 at DA Davidson
04/14/20 Jefferies
Prestige Consumer downgraded to Hold at Jefferies as data weakens
PBH Prestige Consumer
/

+

PBH Prestige Consumer
/

+

Recommendations
Molecular Templates files $300M mixed securities shelf  07:50
08/07/20
08/07
07:50
08/07/20
07:50
MTEM

Molecular Templates

$11.13 /

-0.15 (-1.33%)

 
ShowHide Related Items >><<
MTEM Molecular Templates
$11.13 /

-0.15 (-1.33%)

MTEM Molecular Templates
$11.13 /

-0.15 (-1.33%)

05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/27/20 Barclays
Molecular Templates initiated with an Overweight at Barclays
MTEM Molecular Templates
$11.13 /

-0.15 (-1.33%)

  • 21
    Nov
Upgrade
BofA upgrades First Solar to Buy on higher visibility and confidence » 07:49
08/07/20
08/07
07:49
08/07/20
07:49
FSLR

First Solar

$64.42 /

-1.315 (-2.00%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

07:42 Today BofA
First Solar upgraded to Buy from Neutral at BofA
07:00 Today UBS
First Solar price target raised to $75 from $63 at UBS
06:34 Today Roth Capital
First Solar price target raised to $65 from $56 at Roth Capital
06:27 Today Barclays
First Solar price target lowered to $45 from $51 at Barclays
FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

FSLR First Solar
$64.42 /

-1.315 (-2.00%)

Hot Stocks
AnPac Bio validating approved COVID-19 antibody test » 07:48
08/07/20
08/07
07:48
08/07/20
07:48
ANPC

AnPac Bio

$5.50 /

-0.3 (-5.17%)

AnPac Bio-Medical Science…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANPC AnPac Bio
$5.50 /

-0.3 (-5.17%)

ANPC AnPac Bio
$5.50 /

-0.3 (-5.17%)

  • 30
    Jan
Hot Stocks
Sabre sees $275M in cost savings in 2020 » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

"Our thoughts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Hot Stocks
Arbutus cannot predict negative impacts from COVID-19 on plans, timelines » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In December 2019 an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Arbutus entitled to receive tiered low single digit royalties on Genevant sales » 07:46
08/07/20
08/07
07:46
08/07/20
07:46
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

On July 23, 2020, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Sabre not giving guidance at this time » 07:45
08/07/20
08/07
07:45
08/07/20
07:45
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

Given the magnitude and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Recommendations
Uber price target raised to $46 from $44 at Morgan Stanley » 07:45
08/07/20
08/07
07:45
08/07/20
07:45
UBER

Uber

$34.70 /

+1.49 (+4.49%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

07:26 Today Wedbush
Uber price target lowered to $41 from $47 at Wedbush
06:42 Today Mizuho
Uber price target raised to $42 from $40 at Mizuho
06:28 Today KeyBanc
Uber's results likely to remain 'inconsistent' in the near-term, says KeyBanc
06:24 Today Barclays
Uber price target raised to $43 from $39 at Barclays
UBER Uber
$34.70 /

+1.49 (+4.49%)

  • 11
    Feb
  • 07
    Nov
  • 06
    Nov
UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

UBER Uber
$34.70 /

+1.49 (+4.49%)

General news
Treasury Market Outlook: nervousness ahead of the jobs report has weighed slightly on equities » 07:45
08/07/20
08/07
07:45
08/07/20
07:45

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Sabre CEO says 'overall travel environment remains severely depressed' » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

"This remains an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Hot Stocks
Arbutus Biopharma sees 2020 cash burn $54M-$58M » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Earlier this year, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Hot Stocks
Arbutus Biopharma expects to complete IND-enabling studies of AB-836 by year-end » 07:44
08/07/20
08/07
07:44
08/07/20
07:44
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

In January 2020, Arbutus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Recommendations
AMN Healthcare price target raised to $65 from $50 at BMO Capital » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
AMN

AMN Healthcare

$55.22 /

-0.7 (-1.25%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
07/21/20 SunTrust
AMN Healthcare upgraded to Buy from Hold at SunTrust
05/13/20 BMO Capital
AMN Healthcare price target lowered to $50 from $79 at BMO Capital
05/12/20 Credit Suisse
AMN Healthcare price target lowered to $62 from $81 at Credit Suisse
AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

AMN AMN Healthcare
$55.22 /

-0.7 (-1.25%)

Hot Stocks
Arbutus expects results from cohort in AB-729 trial in 2H20 » 07:43
08/07/20
08/07
07:43
08/07/20
07:43
ABUS

Arbutus Biopharma

$4.39 /

+0.215 (+5.16%)

Arbutus is dosing two 60…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

ABUS Arbutus Biopharma
$4.39 /

+0.215 (+5.16%)

Earnings
Sabre reports Q2 adjusted EPS ($1.30), consensus (84c) » 07:42
08/07/20
08/07
07:42
08/07/20
07:42
SABR

Sabre

$8.29 /

+0.105 (+1.28%)

Reports Q2 revenue $83M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

05/11/20 Bernstein
Bernstein upgrades Sabre to Outperform ahead of air travel returning
05/11/20
Sabre upgraded to Outperform from Market Perform at Bernstein
04/13/20 Mizuho
Sabre price target raised to $5 from $3 at Mizuho
03/23/20 Mizuho
Sabre downgraded to Underperform from Buy at Mizuho
SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

SABR Sabre
$8.29 /

+0.105 (+1.28%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.